PMID- 28324148
OWN - NLM
STAT- MEDLINE
DCOM- 20190909
LR  - 20190909
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 77
IP  - 5
DP  - 2018 Jun
TI  - Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients 
      with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized 
      controlled trials.
PG  - 421-428
LID - 10.1007/s00393-017-0292-6 [doi]
AB  - OBJECTIVE: This study aimed to assess the relative efficacy and tolerability of 
      every other week (q2w) dosing of sarilumab 150 and 200 mg in patients with active 
      rheumatoid arthritis (RA). METHODS: In this network meta-analysis, randomized 
      controlled trials (RCTs) examining the efficacy and tolerability of sarilumab in 
      patients with active RA were included. A Bayesian network meta-analysis was 
      conducted to combine the direct and indirect evidence from the RCTs. RESULTS: 
      Four RCTs, involving 2667 patients, met the inclusion criteria. The American 
      College of Rheumatology (ACR)50 response rate was significantly higher in the 
      sarilumab 200 mg and sarilumab 200 mg + methotrexate (MTX) groups than in the 
      placebo + MTX group (odds ratio, OR, of 4.05, 95% credible interval, CrI, of 
      2.04-8.33 and OR of 3.75, 95% CrI of 2.37-5.72, respectively). Compared to the 
      placebo + MTX group, the sarilumab 150 mg + MTX and adalimumab 40 mg groups 
      showed a significantly higher ACR50 response rate. The ranking probability based 
      on the surface under the cumulative ranking curve (SUCRA) indicated that 
      sarilumab 200 mg was likely to achieve the best ACR50 response rate (SUCRA = 
      0.8518), followed by sarilumab 200 mg + MTX (SUCRA = 0.8225), sarilumab 150 mg + 
      MTX (SUCRA = 0.5112), adalimumab 40 mg (SUCRA = 0.3072), and placebo + MTX 
      (SUCRA = 0.0072). The ACR50 and ACR70 response rate distributions were 
      comparable, except that sarilumab 200 mg + MTX was likely to achieve the best 
      ACR70 response rate. The tolerability based on the number of patient withdrawals 
      due to adverse events (AEs) did not differ significantly between the treatments, 
      except that placebo + MTX was likely to be the best tolerated. CONCLUSION: 
      Sarilumab 150 and 200 mg are efficacious treatments for active RA and are well 
      tolerated.
FAU - Bae, S-C
AU  - Bae SC
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Lee, Y H
AU  - Lee YH
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University Anam 
      Hospital, Korea University College of Medicine, 73, Inchon-ro, 02841, Seoul, 
      Republic of Korea. lyhcgh@korea.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Vergleichbare Wirksamkeit und Vertraglichkeit von Sarilumab 150 und 200 mg bei 
      Patienten mit aktiver rheumatoider Arthritis : Eine Bayes-Netzwerk-Metaanalyse 
      randomisierter kontrollierter Studien.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - NU90V55F8I (sarilumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Antibodies, Monoclonal, Humanized/administration & dosage
MH  - *Antirheumatic Agents/administration & dosage
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Bayes Theorem
MH  - Humans
MH  - Methotrexate
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - Network meta-analysis
OT  - Rheumatoid arthritis
OT  - Sarilumab
OT  - Tolerability
EDAT- 2017/03/23 06:00
MHDA- 2019/09/10 06:00
CRDT- 2017/03/22 06:00
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2019/09/10 06:00 [medline]
PHST- 2017/03/22 06:00 [entrez]
AID - 10.1007/s00393-017-0292-6 [pii]
AID - 10.1007/s00393-017-0292-6 [doi]
PST - ppublish
SO  - Z Rheumatol. 2018 Jun;77(5):421-428. doi: 10.1007/s00393-017-0292-6.